The Market Tithe · Dated receipts, not prophecies
Peptide Stocks & Market Watchlist
Educational market reporting with fictional satire—not investment advice.
Profitide · Fictional Keeper of the Peptide Market Ledger
Follow the public companies developing peptide medicines—and the manufacturers, testing laboratories, device makers and logistics businesses supporting them. This is a research watchlist, not a list of stocks to buy.
Market snapshot: October 1, 2026 close. All 15 companies now share one ledger with prices, YTD performance and sourced analyst coverage. Read the October 2 Market Tithe →
Market close: Oct. 1, 2026YTD price returnData: WSJ / MarketWatch / FactSetNo investment recommendation
Fictional comment—Profitide: “The molecule may be tiny, but apparently it still requires a factory, a filing and seventeen conference calls.”
The complete market ledger
15 companies. One view.
Same fields for every company. Category colors describe the business, not investment quality. Broader suppliers and laboratories are not pure peptide investments.
Prices and YTD: October 1, 2026 close in each listing’s market. Ratings reviewed October 2, 2026. This is a dated snapshot, not a live feed.
| Company / listing | Closing price | YTD | Analyst consensus | Sources & latest |
|---|---|---|---|---|
| Eli Lilly and CompanyLLY · NYSEDrug developersTirzepatide medicines and metabolic pipeline | Closing priceUSD 1,149.85 | YTD price return+6.99% | Analyst consensusOverweight32 ratings reported | Data source ↗Analyst ratings ↗Google Finance ↗ |
| Novo Nordisk A/S ADRNVO · NYSEDrug developersDiabetes and obesity medicines; U.S. ADR | Closing priceUSD 37.40 | YTD price return-26.49% | Analyst consensusHold5 ratings reported | Data source ↗Analyst ratings ↗Google Finance ↗ |
| AmgenAMGN · NasdaqDrug developersDiversified biotechnology; MariTide obesity pipeline | Closing priceUSD 407.27 | YTD price return+24.43% | Analyst consensusHold37 ratings reported | Data source ↗Analyst ratings ↗Google Finance ↗ |
| Viking TherapeuticsVKTX · NasdaqDrug developersInvestigational metabolic medicines including VK2735 | Closing priceUSD 30.51 | YTD price return-13.27% | Analyst consensusBuy20 ratings reported | Data source ↗Analyst ratings ↗Google Finance ↗ |
| Bachem HoldingBANB · SIX SwissManufacturing & APIsPeptide and oligonucleotide development and manufacturing | Closing priceCHF 78.75 | YTD price return+31.47% | Analyst consensusNot verified13 ratings reported | Data source ↗Analyst ratings ↗Google Finance ↗ |
| PolyPeptide GroupPPGN · SIX SwissManufacturing & APIsContract peptide development and manufacturing | Closing priceCHF 44.10 | YTD price return+68.97% | Analyst consensusNot verified6 ratings reported | Data source ↗Analyst ratings ↗Google Finance ↗ |
| Lonza GroupLONN · SIX SwissManufacturing & APIsDiversified contract development and manufacturing | Closing priceCHF 560.60 | YTD price return+4.24% | Analyst consensusNot verified28 ratings reported | Data source ↗Analyst ratings ↗Google Finance ↗ |
| Thermo Fisher ScientificTMO · NYSEManufacturing & APIsLaboratory equipment, services and pharmaceutical manufacturing | Closing priceUSD 652.51 | YTD price return+12.61% | Analyst consensusOverweight30 ratings reported | Data source ↗Analyst ratings ↗Google Finance ↗ |
| Stevanato GroupSTVN · NYSEDelivery & packagingDrug containment, delivery systems and production equipment | Closing priceUSD 19.98 | YTD price return-0.70% | Analyst consensusOverweight14 ratings reported | Data source ↗Analyst ratings ↗Google Finance ↗ |
| West Pharmaceutical ServicesWST · NYSEDelivery & packagingInjectable-drug packaging and delivery components | Closing priceUSD 365.01 | YTD price return+32.66% | Analyst consensusBuy20 ratings reported | Data source ↗Analyst ratings ↗Google Finance ↗ |
| GerresheimerGXI · XetraDelivery & packagingPharmaceutical packaging and delivery systems | Closing priceEUR 27.72 | YTD price return+0.51% | Analyst consensusNot verified14 ratings reported | Data source ↗Analyst ratings ↗Google Finance ↗ |
| Charles River LaboratoriesCRL · NYSETesting & developmentPreclinical research and drug-development services | Closing priceUSD 286.83 | YTD price return+43.79% | Analyst consensusOverweight21 ratings reported | Data source ↗Analyst ratings ↗Google Finance ↗ |
| LabcorpLH · NYSETesting & developmentDiagnostic testing and biopharma laboratory services | Closing priceUSD 304.60 | YTD price return+21.41% | Analyst consensusOverweight21 ratings reported | Data source ↗Analyst ratings ↗Google Finance ↗ |
| Quest DiagnosticsDGX · NYSETesting & developmentClinical diagnostic testing; broader healthcare exposure | Closing priceUSD 231.09 | YTD price return+33.17% | Analyst consensusOverweight20 ratings reported | Data source ↗Analyst ratings ↗Google Finance ↗ |
| Eurofins ScientificERF · Euronext ParisTesting & developmentBioanalytical, pharmaceutical and other laboratory testing | Closing priceEUR 74.54 | YTD price return+19.46% | Analyst consensusNot verified13 ratings reported | Data source ↗Analyst ratings ↗Google Finance ↗ |
“Not verified” means the source reports an analyst count but its aggregate rating could not be confirmed. It does not mean no analysts cover the company. U.S. data: WSJ / FactSet. European data: MarketWatch / FactSet. Each row links to its source; external pages may show newer figures or require a subscription.
How to read the ledger
Three numbers, three different meanings
What is reported
- YTD performance is share-price change from the prior year-end close to the dated market close; dividends are excluded.
- Analyst consensus is an aggregation of third-party ratings. It is not the Church’s or Profitide’s rating.
- Coverage count shows how many analyst opinions sit behind that consensus; a rating with fewer analysts is not equivalent to one with broad coverage.
What is not claimed
- A rising stock does not prove a medicine works.
- A favorable rating is not a prediction or recommendation.
- One news event is not assigned as the cause of a price move without event-specific evidence.
- Companies do not purchase inclusion, classification or favorable treatment.
Market-data note: Prices and YTD price returns are in the listed currency, through October 1, 2026 local market close; no currency conversion or dividends are included. Analyst opinions and coverage can change. Labels such as “Buy” are the provider’s aggregate opinions, not recommendations from Profitide or Church of Peptides. Educational reporting only—not investment advice.
The Pilgrimage · From Molecule to Medicine
Follow one fictional peptide through discovery, trials, funding, approval and the realities of launch.
Explore the eight-chapter journey →